Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission

NCT04968015 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT04968015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04968015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 25, 2022
Completion date
January 31, 2029
Enrollment
134 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia